Tumor-associated antigens in effusions of malignant and benign origin
- PMID: 8353402
- DOI: 10.1007/BF00180056
Tumor-associated antigens in effusions of malignant and benign origin
Abstract
We determined the concentration and effusion/serum ratio of mucin-like carcinoma-associated antigen (MCA) in comparison to carcinoembryonic antigen, carbohydrate antigen 19-9, cancer antigen 125, and cancer antigen 15-3 in 80 sera and 99 effusions from 64 patients with histologically confirmed malignancies (4 patients out of this group showed various effusions simultaneously, which were analyzed separately) and 31 patients with various nonneoplastic diseases. Tumor cells were detected by cytological examination in 41 effusions (60.3%) from patients with neoplastic diseases, while in another 27 cases this method failed to demonstrate the malignant origin of the effusion. Of the cytological "positive" malignant effusions 90% were also correctly identified by an elevated MCA concentration at a cutoff level of 10 U/ml, whereas only one effusion of benign origin (3%) showed a slightly elevated MCA concentration of 10.5 U/ml. In 33% of cytologically "negative" effusions of patients with neoplastic diseases, the MCA concentration was also elevated, with a maximum of 453 U/ml. Increased MCA levels in cytologically confirmed malignant effusions were not restricted to metastatic breast cancer. All 17 cytologically "positive" "non-breast cancer" effusions were correctly identified by their MCA concentrations. None of the other tumor markers reached this high sensitivity at the same level of specificity. The ratio of effusion/serum concentration of all tumor markers as well as the concentration of cancer antigen 125 in effusions was of little diagnostic value. Our results indicate that the MCA concentration in an effusion correlates very closely with its malignant origin and is superior to all the other antigens tested.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Tumor markers in the diagnosis of malignant serous effusions.Am J Clin Oncol. 1997 Jun;20(3):247-50. doi: 10.1097/00000421-199706000-00007. Am J Clin Oncol. 1997. PMID: 9167746
-
Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions.Chest. 2004 Dec;126(6):1757-63. doi: 10.1378/chest.126.6.1757. Chest. 2004. PMID: 15596670
-
Diagnostic significance of the tumour markers CEA, CA 15-3 and CA 125 in malignant effusions in breast cancer.Ann Oncol. 1990 Nov;1(6):435-8. doi: 10.1093/oxfordjournals.annonc.a057798. Ann Oncol. 1990. PMID: 2083187
-
Evaluation of predictive value of pleural CEA in patients with pleural effusions and histological findings: A prospective study and literature review.Clin Biochem. 2016 Nov;49(16-17):1227-1231. doi: 10.1016/j.clinbiochem.2016.08.006. Epub 2016 Aug 10. Clin Biochem. 2016. PMID: 27521620 Review.
-
Pleural effusion as a sample matrix for laboratory analyses in cancer management: a perspective.Clin Chem Lab Med. 2025 Mar 3;63(6):1069-1074. doi: 10.1515/cclm-2025-0197. Print 2025 May 26. Clin Chem Lab Med. 2025. PMID: 40019933 Review.
Cited by
-
The value of serum tumour markers in the prediction of aetiology and follow up of patients with pericardial effusion.Cardiovasc J Afr. 2012 Apr;23(3):143-6. doi: 10.5830/CVJA-2011-029. Cardiovasc J Afr. 2012. PMID: 22555638 Free PMC article.
-
Value of carcinoembryonic antigen (CEA) and cholesterol assays of ascitic fluid in cases of inconclusive cytology.J Clin Pathol. 2001 Nov;54(11):831-5. doi: 10.1136/jcp.54.11.831. J Clin Pathol. 2001. PMID: 11684715 Free PMC article.
-
Use of cholesterol and soluble tumour markers CEA and syndecan-2 in pleural effusions in cases of inconclusive cytology.J Clin Pathol. 2019 Aug;72(8):529-535. doi: 10.1136/jclinpath-2018-205650. Epub 2019 Apr 26. J Clin Pathol. 2019. PMID: 31028099 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials